Antisoma plc entered a deal with F. Hoffmann-La Roche Ltd. that has a headline value of US$500 million, including up-front payments of $43 million, more than Antisoma's market capitalization of £26.4 million when the markets closed Friday. (BioWorld Today)

Antisoma plc entered a deal with F. Hoffmann-La Roche Ltd. that has a headline value of US$500 million, including up-front payments of $43 million, more than Antisoma's market capitalization of £26.4 million when the markets closed Friday. (BioWorld Today)